See attached document. Signum has entered into an agreement with GlaxoSmithKline (China) R&D Company Limited (GSK) to collaborate on Signum’s phosphatase screening technology and Phosphoprotein Phosphatase 2A (PP2A). GSK and Signum will undertake a broad R&D collaboration to screen and identify PP2A targeted compounds including those bridging the link between PP2A methylation and tau hyperphosphorylation. Press release.